Cargando…

Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden

SIMPLE SUMMARY: MIB-1 index is an established immunohistochemical marker reflecting the proliferative potential in meningiomas. Cyclooxygenase-2 has been demonstrated to be positively correlated with MIB-1 index in meningiomas. In a recent investigation, we revealed that cranial non-skull-base menin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wach, Johannes, Güresir, Ági, Vatter, Hartmut, Herrlinger, Ulrich, Becker, Albert, Toma, Marieta, Hölzel, Michael, Güresir, Erdem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454729/
https://www.ncbi.nlm.nih.gov/pubmed/36077817
http://dx.doi.org/10.3390/cancers14174285
_version_ 1784785419041243136
author Wach, Johannes
Güresir, Ági
Vatter, Hartmut
Herrlinger, Ulrich
Becker, Albert
Toma, Marieta
Hölzel, Michael
Güresir, Erdem
author_facet Wach, Johannes
Güresir, Ági
Vatter, Hartmut
Herrlinger, Ulrich
Becker, Albert
Toma, Marieta
Hölzel, Michael
Güresir, Erdem
author_sort Wach, Johannes
collection PubMed
description SIMPLE SUMMARY: MIB-1 index is an established immunohistochemical marker reflecting the proliferative potential in meningiomas. Cyclooxygenase-2 has been demonstrated to be positively correlated with MIB-1 index in meningiomas. In a recent investigation, we revealed that cranial non-skull-base meningiomas have increased proliferative potential and increased inflammatory burden compared to other anatomical locations of meningiomas. The role of nonsteroidal anti-inflammatory drugs (NSAIDs) regarding proliferative activity and location-specific symptoms in non-skull-base meningiomas is unclear so far. In the present investigation, we therefore analyzed the impact of low-dose (100 mg) acetylsalicylic acid (ASA) treatment on the MIB-1 index and baseline symptomatic epilepsy. We identified that elderly female non-skull-base meningioma patients with ASA intake had significantly lower MIB-1 indices. Furthermore, ASA intake significantly reduced the preoperative seizure burden in non-skull-base meningioma. We believe that further research on NSAID treatment in non-skull-base meningiomas is necessary to enhance a tailored treatment scheduling. ABSTRACT: MIB-1 index is an important predictor of meningioma progression and was found to be correlated with COX-2 expression. However, the impact of low-dose acetylsalicylic acid (ASA) on MIB-1 index and clinical symptoms is unclear. Between 2009 and 2022, 710 patients with clinical data, tumor-imaging data, inflammatory laboratory (plasma fibrinogen, serum C-reactive protein) data, and neuropathological reports underwent surgery for primary cranial WHO grade 1 and 2 meningioma. ASA intake was found to be significantly associated with a low MIB-1 labeling index in female patients ≥ 60 years. Multivariable analysis demonstrated that female patients ≥ 60 years with a non-skull-base meningioma taking ASA had a significantly lower MIB-1 index (OR: 2.6, 95%: 1.0–6.6, p = 0.04). Furthermore, the intake of ASA was independently associated with a reduced burden of symptomatic epilepsy at presentation in non-skull-base meningiomas in both genders (OR: 3.8, 95%CI: 1.3–10.6, p = 0.03). ASA intake might have an anti-proliferative effect in the subgroup of elderly female patients with non-skull-base meningiomas. Furthermore, anti-inflammatory therapy seems to reduce the burden of symptomatic epilepsy in non-skull-base meningiomas. Further research is needed to investigate the role of anti-inflammatory therapy in non-skull-base meningiomas.
format Online
Article
Text
id pubmed-9454729
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94547292022-09-09 Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden Wach, Johannes Güresir, Ági Vatter, Hartmut Herrlinger, Ulrich Becker, Albert Toma, Marieta Hölzel, Michael Güresir, Erdem Cancers (Basel) Article SIMPLE SUMMARY: MIB-1 index is an established immunohistochemical marker reflecting the proliferative potential in meningiomas. Cyclooxygenase-2 has been demonstrated to be positively correlated with MIB-1 index in meningiomas. In a recent investigation, we revealed that cranial non-skull-base meningiomas have increased proliferative potential and increased inflammatory burden compared to other anatomical locations of meningiomas. The role of nonsteroidal anti-inflammatory drugs (NSAIDs) regarding proliferative activity and location-specific symptoms in non-skull-base meningiomas is unclear so far. In the present investigation, we therefore analyzed the impact of low-dose (100 mg) acetylsalicylic acid (ASA) treatment on the MIB-1 index and baseline symptomatic epilepsy. We identified that elderly female non-skull-base meningioma patients with ASA intake had significantly lower MIB-1 indices. Furthermore, ASA intake significantly reduced the preoperative seizure burden in non-skull-base meningioma. We believe that further research on NSAID treatment in non-skull-base meningiomas is necessary to enhance a tailored treatment scheduling. ABSTRACT: MIB-1 index is an important predictor of meningioma progression and was found to be correlated with COX-2 expression. However, the impact of low-dose acetylsalicylic acid (ASA) on MIB-1 index and clinical symptoms is unclear. Between 2009 and 2022, 710 patients with clinical data, tumor-imaging data, inflammatory laboratory (plasma fibrinogen, serum C-reactive protein) data, and neuropathological reports underwent surgery for primary cranial WHO grade 1 and 2 meningioma. ASA intake was found to be significantly associated with a low MIB-1 labeling index in female patients ≥ 60 years. Multivariable analysis demonstrated that female patients ≥ 60 years with a non-skull-base meningioma taking ASA had a significantly lower MIB-1 index (OR: 2.6, 95%: 1.0–6.6, p = 0.04). Furthermore, the intake of ASA was independently associated with a reduced burden of symptomatic epilepsy at presentation in non-skull-base meningiomas in both genders (OR: 3.8, 95%CI: 1.3–10.6, p = 0.03). ASA intake might have an anti-proliferative effect in the subgroup of elderly female patients with non-skull-base meningiomas. Furthermore, anti-inflammatory therapy seems to reduce the burden of symptomatic epilepsy in non-skull-base meningiomas. Further research is needed to investigate the role of anti-inflammatory therapy in non-skull-base meningiomas. MDPI 2022-09-01 /pmc/articles/PMC9454729/ /pubmed/36077817 http://dx.doi.org/10.3390/cancers14174285 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wach, Johannes
Güresir, Ági
Vatter, Hartmut
Herrlinger, Ulrich
Becker, Albert
Toma, Marieta
Hölzel, Michael
Güresir, Erdem
Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden
title Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden
title_full Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden
title_fullStr Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden
title_full_unstemmed Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden
title_short Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden
title_sort low-dose acetylsalicylic acid treatment in non-skull-base meningiomas: impact on tumor proliferation and seizure burden
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454729/
https://www.ncbi.nlm.nih.gov/pubmed/36077817
http://dx.doi.org/10.3390/cancers14174285
work_keys_str_mv AT wachjohannes lowdoseacetylsalicylicacidtreatmentinnonskullbasemeningiomasimpactontumorproliferationandseizureburden
AT guresiragi lowdoseacetylsalicylicacidtreatmentinnonskullbasemeningiomasimpactontumorproliferationandseizureburden
AT vatterhartmut lowdoseacetylsalicylicacidtreatmentinnonskullbasemeningiomasimpactontumorproliferationandseizureburden
AT herrlingerulrich lowdoseacetylsalicylicacidtreatmentinnonskullbasemeningiomasimpactontumorproliferationandseizureburden
AT beckeralbert lowdoseacetylsalicylicacidtreatmentinnonskullbasemeningiomasimpactontumorproliferationandseizureburden
AT tomamarieta lowdoseacetylsalicylicacidtreatmentinnonskullbasemeningiomasimpactontumorproliferationandseizureburden
AT holzelmichael lowdoseacetylsalicylicacidtreatmentinnonskullbasemeningiomasimpactontumorproliferationandseizureburden
AT guresirerdem lowdoseacetylsalicylicacidtreatmentinnonskullbasemeningiomasimpactontumorproliferationandseizureburden